Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,306 total articles
Mobilicom Limited (Nasdaq: MOB) will participate in two significant U.S. events, XPONENTIAL 2026 and Loitering Munitions USA, showcasing its cybersecurity-focused autonomous drone and robotics solutions. CEO Oren Elkayam will present on preventing cascade failures in autonomous fleets, highlighting the company's innovation and role in secured auton…
Advanced Flower Capital Inc. announced solid financial results for Q1 2026, including GAAP net investment income of $4.8 million and net asset value per share increase to $7.90. The company repaid dividends exceeding net investment income and initiated a $5 million share repurchase program to enhance shareholder value. AFC's focus on flexible credi…
MasterCraft Boat Holdings, Inc. reported Q3 fiscal 2026 net sales of $78.2 million, a 3% increase year over year, and adjusted net income of $7.2 million, up from $5.0 million in the prior year. Adjusted EBITDA rose to $10.7 million, reflecting improved operational efficiency despite a GAAP loss due to one-time transaction costs related to its pend…
Vera Therapeutics announced that the FDA has granted priority review to the Biologics License Application for atacicept, targeting accelerated approval for treatment of IgA Nephropathy with a PDUFA date set for July 7, 2026. The company is progressing preparations for a U.S. commercial launch pending approval, strengthened its executive team, and r…
ARKO Corp., a major U.S. convenience store operator and fuel wholesaler, reported improved Q1 2026 financials with net loss narrowing to $5.6 million from $12.7 million a year ago. Adjusted EBITDA surged 65.1% to $50.9 million driven by growth in merchandise margins and same-store fuel margins. The company made substantial progress in converting re…
Repligen Corporation, a leader in bioprocessing technologies for biopharmaceutical manufacturing, announced its participation in the Bank of America Securities 2026 Global Healthcare Conference with CFO Jason Garland leading a discussion. The event will be webcast live and available for replay, highlighting the company's ongoing engagement with inv…
nCino, Inc. announced that Vision Credit Union, a major Alberta-based credit union with significant agricultural loan exposure, has chosen nCino’s commercial lending, banking advisor, and automated spreading solutions to digitize and enhance its lending operations. The new technology will automate manual workflows and provide AI-driven insights, en…
SL Green Realty Corp., Manhattan's largest office landlord, announced that One Madison Avenue was honored with the 2026 Urban Land Institute Award for Excellence in Office Development. The project exemplifies adaptive reuse, sustainability, and high tenant demand, with the building achieving 100% occupancy and notable rents. The redevelopment featu…
BriaCell Therapeutics announced the addition of NYU Langone Health's Perlmutter Cancer Center as a site for its pivotal Phase 3 clinical trial evaluating Bria-IMT™ immunotherapy in advanced metastatic breast cancer. The study tests Bria-IMT combined with an immune checkpoint inhibitor versus physician's choice treatment. The trial has FDA Fast Trac…
Annovis Bio's CEO will present on the multi-protein model of Alzheimer's Disease, advocating a shift from the traditional single-protein focus to targeting multiple neurotoxic proteins. The company's lead drug, buntanetap, targets several misfolded proteins and is currently in Phase 3 trials, showing promising clinical benefits and biomarker data.
MACOM Technology Solutions Holdings, Inc. announced robust fiscal second quarter 2026 results, with revenue of $289 million, a 22.5% increase year-over-year, and strong margin expansion. Adjusted net income rose significantly to $84.3 million, or $1.09 per diluted share. The company projects continued growth for the fiscal third quarter with expect…
Black Diamond Therapeutics reported Q1 2026 results showcasing $118.3 million in cash and investments, sufficient to fund operations into late 2028. The company advanced its clinical-stage oncology drug, silevertinib, with key Phase 2 trial presentations scheduled at ASCO 2026, including data on frontline EGFRm NSCLC and newly diagnosed EGFRvIII+ G…
Collegium Pharmaceutical, Inc. reported a 9% year-over-year increase in quarterly net revenues to $193.5 million for Q1 2026, driven by a 36% growth in JORNAY PM sales. The company is on track to acquire AZSTARYS, a complementary ADHD treatment, expected in Q2 2026, which will enhance its ADHD portfolio and expand growth potential. Pain portfolio r…
Stardust Power Inc., a US-based developer of battery-grade lithium carbonate, announced it will release its Q1 2026 financial results on May 14, 2026, after market close. The company will host a conference call the same day to discuss the results and provide updates on its strategic lithium refinery project in Oklahoma aiming to support America's e…
urban-gro, Inc., via its subsidiary Innovative Production Group FZ, LLC (IPG), announces its commercial involvement in the Lanka Premier League Season 6, scheduled for July-August 2026 in Sri Lanka. The company highlights the opening of the foreign player registration portal on May 8, 2026, and emphasizes its role as a sports, media, and experienti…
Ascendis Pharma reported strong financial results for Q1 2026, driven by significant revenue growth from its commercial products, especially YORVIPATH, which generated €197 million. The company successfully launched YUVIWEL in the U.S. with over 60 patient enrollments since April. The company plans further clinical trials and market expansions and …
Plus Therapeutics announced that its subsidiary CNSide Diagnostics has been approved for Medicare enrollment, allowing billing for its CNSide CSF Assay diagnostic test for CNS cancers. This milestone facilitates access to Medicare beneficiaries, supports reimbursement processes, and strengthens commercialization efforts with national and regional p…
Palvella Therapeutics reported strong Q1 2026 results highlighting positive Phase 3 data for QTORIN™ rapamycin in microcystic lymphatic malformations, an FDA Pre-NDA meeting scheduled for Q2 2026, and a planned NDA submission in H2 2026. The company also secured $230 million in oversubscribed equity financing to fund commercialization and pipeline …
Lexicon Pharmaceuticals reported a significant reduction in net loss for Q1 2026, driven by milestone payments and controlled expenses. The company is advancing pivotal clinical trials for sotagliflozin in hypertrophic cardiomyopathy and type 1 diabetes, with anticipated regulatory submissions and approvals within 2026. Licensing agreements with No…
Harvard Bioscience, Inc., a developer and manufacturer of life science technologies, announced that its CEO John Duke and CFO Mark Frost will participate in two upcoming virtual investor conferences in May 2026, including the Sidoti Micro Cap Conference and the Benchmark Healthcare House Call Virtual Conference. The company will provide a live webc…
Kelly Services reported a 10.7% decline in Q1 2026 revenue to $1.0 billion, impacted by weaker demand in certain segments and discrete customer impacts. The company posted a $5.1 million operating loss but an adjusted operating income of $4.1 million. Cost reduction efforts led to a 10.3% decline in SG&A expenses. Kelly affirmed its outlook for gra…
QuasarEdge Acquisition Corporation (NYSE: QRED) has signed a non-binding letter of intent to acquire Robseek Intelligence Inc., an infrastructure platform company focused on AI-driven device distribution and data services primarily in the Middle East. The proposed transaction involves a share-for-share exchange, aiming to bring Robseek public throu…
Evaxion A/S, a clinical-stage TechBio company specializing in AI-based vaccine development, announced its first quarter 2026 financial results alongside key business updates. The company demonstrated strong progress with new data validating their AI-Immunology™ platform’s high precision in cancer vaccine target recognition and scalability in gliobl…
EDAP TMS SA reported strong financial results for Q1 2026, driven by a record $11.6 million in High-Intensity Focused Ultrasound (HIFU) revenue, representing 78% growth year-over-year. The company achieved its seventh consecutive quarter of HIFU revenue growth, with key markets in the U.S. and Europe expanding capital sales of the Focal One Robotic…
Alterity Therapeutics will present significant clinical data and updates on its lead drug ATH434 targeting Multiple System Atrophy (MSA) at several international medical conferences in May 2026. The presentations include promising Phase 2 trial results and plans for a Phase 3 pivotal study, underscoring the company's advancement in developing disea…
